{
  "id": 18479795,
  "title": "Canaccord reiterates Natera stock rating on strong Q3 results",
  "url": "https://urgent.news/2026/11/06/canaccord-reiterates-natera-stock-rating-on-strong-q3-results",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-06T09:52:54.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/canaccord-reiterates-natera-stock-rating-on-strong-q3-results-93CH-5007060"
  },
  "original_language": "en",
  "account": "Investing.com reports that Canaccord Genuity has maintained its Buy rating and $500 price target for Natera Inc. (NASDAQ:NTRA) following the company's strong third-quarter results in 2026. Natera surpassed analyst estimates and FactSet consensus with its Q3 performance, driven by continued strength in Signatera and momentum in Women's Health. However, the stock has declined by 12.2% over the past week, trading at $363.76, despite an impressive 83% return over the past year. Despite the stock's high revenue valuation multiple, analysts do not expect profitability this year. In other developments, Solomon Moshkevich, President of Clinical Diagnostics, has been appointed CEO of Natera, succeeding Steve Chapman. The company has raised its 2026 revenue outlook to $3.005 billion to $3.035 billion and increased operating expense guidance. Despite positive financial results, the stock's decline suggests investor concerns about the company's near-term outlook and spending pace.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}